Abstract: Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I) and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Abstract: The invention provides inhibitors of Wnt signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein R1 to R7 and Z are as defined herein.

Abstract: Methods and products are provided for treating thromboembolic stroke. A method involves the administration of a thienopyridine derivative in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke. Preferably the thienopyridine derivative is ticlopidine and the thrombolytic agent is tPA. The method also involves the administration of a thrombolytic agent to a subject who already has circulating plasma levels of a thienopyridine derivative. The product is a pharmaceutical preparation of a thienopyridine derivative and a thrombolytic agent and a pharmaceutically acceptable carrier.